Invivyd, Inc. Announces Inclusion of PEMGARDA® in NCCN Clinical Practice Guidelines for B-Cell Lymphomas

Invivyd (IVVD) announced that its investigational monoclonal antibody, PEMGARDA (pemivibart), has been added to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for B-Cell Lymphomas, recognizing its potential for pre-exposure prophylaxis against COVID-19 in immunocompromised patients, particularly those with B-cell malignancies. PEMGARDA is currently authorized for emergency use in the U.S. for certain high-risk patients and demonstrates neutralizing activity against major SARS-CoV-2 variants, offering a crucial tool for clinicians in managing vulnerable patients during cancer treatment amid ongoing COVID-19 challenges. Insiders have been net sellers of IVVD stock over the last 6 months, and hedge fund activity has been mixed with some firms increasing and others decreasing their positions.

Analysis

Invivyd, Inc. (IVVD) has achieved a notable milestone with its investigational monoclonal antibody, PEMGARDA® (pemivibart), being added to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for B-Cell Lymphomas. This inclusion signifies recognition of PEMGARDA's potential for pre-exposure prophylaxis (PrEP) against COVID-19 in immunocompromised patients, specifically those with B-cell malignancies who may not achieve an adequate immune response from vaccination. The endorsement by NCCN, following a similar recommendation by the Infectious Disease Society of America (IDSA) in August 2024, enhances PEMGARDA's credibility and may support its clinical adoption for this vulnerable patient segment, especially as it demonstrates neutralizing activity against major SARS-CoV-2 variants like JN.1. However, PEMGARDA operates under an Emergency Use Authorization (EUA), which is temporary and subject to revision or revocation, introducing uncertainty regarding its long-term market presence. The article also highlights concerns about reduced activity against emerging variants and potential safety issues such as anaphylaxis, which carries a boxed warning. Financially, insider sentiment appears negative, with Terrance McGuire executing 15 sales totaling 1,621,322 shares for approximately $836,953 in the past six months, and no insider purchases recorded. Hedge fund activity is mixed but leans towards net selling, with 49 institutions decreasing positions versus 38 increasing. Notably, Slate Path Capital LP and Jacobs Levy Equity Management Inc. completely exited their positions, while FMR LLC, Deep Track Capital, LP, Maverick Capital Ltd, and Redmile Group, LLC also made substantial reductions. Conversely, BlackRock, Inc. increased its stake by 605,758 shares.

Key Decisions for Investors

• Consider the NCCN guideline inclusion as a positive catalyst for PEMGARDA's adoption in a specific high-need patient population, potentially increasing Invivyd's market penetration in the short term.
• Weigh the positive regulatory development against the significant insider selling and net institutional divestment, which may signal concerns about long-term valuation or competitive pressures.
• Monitor closely the durability of PEMGARDA's EUA, its efficacy against evolving SARS-CoV-2 variants, any updates on its path to full regulatory approval, and shifts in institutional holdings for further conviction.